MS-DRG 951

Principal Diagnosis - Pdx

• T40.496A Underdosing of other synthetic narcotics, initial encounter
• T40.5X6A Underdosing of cocaine, initial encounter
• T40.606A Underdosing of unspecified narcotics, initial encounter
• T40.696A Underdosing of other narcotics, initial encounter
• T40.716A Underdosing of cannabis, initial encounter
• T40.726A Underdosing of synthetic cannabinoids, initial encounter
• T40.906A Underdosing of unspecified psychodysleptics [hallucinogens], initial encounter
• T40.996A Underdosing of other psychodysleptics [hallucinogens], initial encounter
• T41.0X6A Underdosing of inhaled anesthetics, initial encounter
• T41.1X6A Underdosing of intravenous anesthetics, initial encounter
• T41.206A Underdosing of unspecified general anesthetics, initial encounter
• T41.296A Underdosing of other general anesthetics, initial encounter
• T41.3X6A Underdosing of local anesthetics, initial encounter
• T41.46XA Underdosing of unspecified anesthetics, initial encounter
• T41.5X6A Underdosing of therapeutic gases, initial encounter
• T42.0X6A Underdosing of hydantoin derivatives, initial encounter
• T42.1X6A Underdosing of iminostilbenes, initial encounter
• T42.2X6A Underdosing of succinimides and oxazolidinediones, initial encounter
• T42.3X6A Underdosing of barbiturates, initial encounter
• T42.4X6A Underdosing of benzodiazepines, initial encounter
• T42.5X6A Underdosing of mixed antiepileptics, initial encounter
• T42.6X6A Underdosing of other antiepileptic and sedative-hypnotic drugs, initial encounter
• T42.76XA Underdosing of unspecified antiepileptic and sedative-hypnotic drugs, initial encounter
• T42.8X6A Underdosing of antiparkinsonism drugs and other central muscle-tone depressants, initial encounter
• T43.016A Underdosing of tricyclic antidepressants, initial encounter
• T43.026A Underdosing of tetracyclic antidepressants, initial encounter
• T43.1X6A Underdosing of monoamine-oxidase-inhibitor antidepressants, initial encounter
• T43.206A Underdosing of unspecified antidepressants, initial encounter
• T43.216A Underdosing of selective serotonin and norepinephrine reuptake inhibitors, initial encounter
• T43.226A Underdosing of selective serotonin reuptake inhibitors, initial encounter
• T43.296A Underdosing of other antidepressants, initial encounter
• T43.3X6A Underdosing of phenothiazine antipsychotics and neuroleptics, initial encounter
• T43.4X6A Underdosing of butyrophenone and thiothixene neuroleptics, initial encounter
• T43.506A Underdosing of unspecified antipsychotics and neuroleptics, initial encounter
• T43.596A Underdosing of other antipsychotics and neuroleptics, initial encounter
• T43.606A Underdosing of unspecified psychostimulants, initial encounter
• T43.616A Underdosing of caffeine, initial encounter
• T43.626A Underdosing of amphetamines, initial encounter
• T43.636A Underdosing of methylphenidate, initial encounter
• T43.656A Underdosing of methamphetamines, initial encounter
• T43.696A Underdosing of other psychostimulants, initial encounter
• T43.8X6A Underdosing of other psychotropic drugs, initial encounter
• T43.96XA Underdosing of unspecified psychotropic drug, initial encounter
• T44.0X6A Underdosing of anticholinesterase agents, initial encounter
• T44.1X6A Underdosing of other parasympathomimetics [cholinergics], initial encounter
• T44.2X6A Underdosing of ganglionic blocking drugs, initial encounter
• T44.3X6A Underdosing of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter
• T44.4X6A Underdosing of predominantly alpha-adrenoreceptor agonists, initial encounter
• T44.5X6A Underdosing of predominantly beta-adrenoreceptor agonists, initial encounter
• T44.6X6A Underdosing of alpha-adrenoreceptor antagonists, initial encounter
• T44.7X6A Underdosing of beta-adrenoreceptor antagonists, initial encounter
• T44.8X6A Underdosing of centrally-acting and adrenergic-neuron-blocking agents, initial encounter
• T44.906A Underdosing of unspecified drugs primarily affecting the autonomic nervous system, initial encounter
• T44.996A Underdosing of other drug primarily affecting the autonomic nervous system, initial encounter
• T45.0X6A Underdosing of antiallergic and antiemetic drugs, initial encounter
• T45.1X6A Underdosing of antineoplastic and immunosuppressive drugs, initial encounter
• T45.2X6A Underdosing of vitamins, initial encounter
• T45.3X6A Underdosing of enzymes, initial encounter
• T45.4X6A Underdosing of iron and its compounds, initial encounter
• T45.516A Underdosing of anticoagulants, initial encounter
• T45.526A Underdosing of antithrombotic drugs, initial encounter
• T45.606A Underdosing of unspecified fibrinolysis-affecting drugs, initial encounter
• T45.616A Underdosing of thrombolytic drugs, initial encounter
• T45.626A Underdosing of hemostatic drugs, initial encounter
• T45.696A Underdosing of other fibrinolysis-affecting drugs, initial encounter
• T45.7X6A Underdosing of anticoagulant antagonist, vitamin K and other coagulants, initial encounter
• T45.8X6A Underdosing of other primarily systemic and hematological agents, initial encounter
• T45.96XA Underdosing of unspecified primarily systemic and hematological agent, initial encounter
• T46.0X6A Underdosing of cardiac-stimulant glycosides and drugs of similar action, initial encounter
• T46.1X6A Underdosing of calcium-channel blockers, initial encounter
• T46.2X6A Underdosing of other antidysrhythmic drugs, initial encounter
• T46.3X6A Underdosing of coronary vasodilators, initial encounter
• T46.4X6A Underdosing of angiotensin-converting-enzyme inhibitors, initial encounter
• T46.5X6A Underdosing of other antihypertensive drugs, initial encounter
• T46.6X6A Underdosing of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter
• T46.7X6A Underdosing of peripheral vasodilators, initial encounter
• T46.8X6A Underdosing of antivaricose drugs, including sclerosing agents, initial encounter
• T46.906A Underdosing of unspecified agents primarily affecting the cardiovascular system, initial encounter
• T46.996A Underdosing of other agents primarily affecting the cardiovascular system, initial encounter
• T47.0X6A Underdosing of histamine H2-receptor blockers, initial encounter
• T47.1X6A Underdosing of other antacids and anti-gastric-secretion drugs, initial encounter
• T47.2X6A Underdosing of stimulant laxatives, initial encounter
• T47.3X6A Underdosing of saline and osmotic laxatives, initial encounter
• T47.4X6A Underdosing of other laxatives, initial encounter
• T47.5X6A Underdosing of digestants, initial encounter
• T47.6X6A Underdosing of antidiarrheal drugs, initial encounter
• T47.7X6A Underdosing of emetics, initial encounter
• T47.8X6A Underdosing of other agents primarily affecting gastrointestinal system, initial encounter
• T47.96XA Underdosing of unspecified agents primarily affecting the gastrointestinal system, initial encounter
• T48.0X6A Underdosing of oxytocic drugs, initial encounter
• T48.1X6A Underdosing of skeletal muscle relaxants [neuromuscular blocking agents], initial encounter
• T48.206A Underdosing of unspecified drugs acting on muscles, initial encounter
• T48.296A Underdosing of other drugs acting on muscles, initial encounter
• T48.3X6A Underdosing of antitussives, initial encounter
• T48.4X6A Underdosing of expectorants, initial encounter
• T48.5X6A Underdosing of other anti-common-cold drugs, initial encounter
• T48.6X6A Underdosing of antiasthmatics, initial encounter
• T48.906A Underdosing of unspecified agents primarily acting on the respiratory system, initial encounter
• T48.996A Underdosing of other agents primarily acting on the respiratory system, initial encounter
• T49.0X6A Underdosing of local antifungal, anti-infective and anti-inflammatory drugs, initial encounter